EuroBiotech—More Articles of Note


> BioMed X and Boehringer Ingelheim added another strand to their multiyear collaboration. The new project will support research into targets for early interventions into psychiatric diseases. Release   

> Nanobiotix unveiled plans to list its stock in the U.S. Statement 

> Boehringer Ingelheim teamed up with Bioharmony Therapeutics to develop bacteriophage lysins to treat multidrug resistant infections. Release 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Sanofi secured access to Biomunex Pharmaceuticals’ technology for optimizing bispecific and multispecific antibodies. Statement (PDF) 

> Shares in Hansa Medical slipped after it revealed the FDA has asked for more information on its kidney disease drug imlifidase. Hansa plans to file for approval in Europe this quarter but is yet to commit to a timeline in the U.S. Release 

> EFPIA reiterated its request to temporarily exempt clinical trial materials from customs checks in the event of a no-deal Brexit after British politicians voted against the withdrawal agreement. Statement

Suggested Articles

NGM's aldafermin beat placebo at reversing liver scarring and inflammation, as well as reducing liver fat buildup in a 78-patient study.

The agreement sees Grifols waive a $32 million debt and pay $3 million in cash to take full ownership of three assets.

Astellas’ Xospata and Novartis’ Rydapt may help treat lung cancer that has grown resistant to EGFR inhibitors, researchers discovered.